Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis
Abstract Background For patients with advanced non-small-cell lung cancer (NSCLC) with EGFR mutations, the suggested course of action is epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs). Even with a high disease control rate, a majority of patients develop acquired EGFR-TKIs r...
Zapisane w:
| Główni autorzy: | , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
BMC
2023-06-01
|
| Seria: | BMC Pulmonary Medicine |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1186/s12890-023-02472-x |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|